Development and optimization of neutralizing antibody assays to monitor clinical immunogenicity

Bioanalysis

Volumn 4, Issue 22, 2012, Pages 2725-2735

  Civoli, Francesca ^a   Kroenke, Mark A ^a   Reynhardt, Kaz ^a   Zhuang, Yao ^a   Kaliyaperumal, Arunan ^a   Gupta, Shalini ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; CELL ASSAY; CELL LINE; CELL SELECTION; CELL THERAPY; CONCENTRATION RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL DESIGN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW;

ANIMALS; ANTIBODIES, NEUTRALIZING; DRUG DISCOVERY; HUMANS; IMMUNITY; IMMUNOASSAY; PROTEINS;

EID: 84870542198     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.239     Document Type: Review

References (31)

1. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 24(11), 1720-1740 (2002). (Pubitemid 35440946)
2. Wadhwa M, Bird C, Dilger P, Gaines-Das R, Thorpe R. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J. Immunol. Methods 278(1-2), 1-17 (2003). (Pubitemid 37281188)
3. Koren E, Smith HW, Shores E et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 333(1-2), 1-9 (2008).
4. Gupta S, Indelicato SR, Jethwa V et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Methods 321(1-2), 1-18 (2007). (Pubitemid 46454303)
5. Gupta S, Devanarayan V, Finco D et al. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J. Pharm. Biomed. Anal. 55(5), 878-888 (2011).
6. Mire-Sluis AR, Barrett YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289(1-2), 1-16 (2004). (Pubitemid 38900899)
7. European Medicines Agency. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. London, UK (2007).
8. US Department of Health and Human Services, US FDA. Guidance for industry. assay development for immunogenicity testing of therapeutic proteins. Silver Spring, MD, USA (2009).
9. Euroepan Medicines Agency. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. London, UK (2012).
10. Novick D, NAbioullin RR, Ragsdale W et al. The neutralization of type I IFN biologic actions by anti-IFNAR-2 monoclonal antibodies is not entirely due to inhibition of Jak-Stat tyrosine phosphorylation. J. Interferon Cytokine Res. 20(11), 971-982 (2000).
11. Pennucci J, Swanson S, Kaliyaperumal A, Gupta S. Multiplexed evaluation of a cell-based assay for the detection of antidrug neutralizing antibodies to panitumumab in human serum using automated fluorescent microscopy. J. Biomol. Screen. 15(6), 644-652 (2010).
12. Moore M, Meager A, Wadhwa M, Burns C. Measurement of neutralising antibodies to type I interferons by gene expression assays specific for type 1 interferon-inducible 6-16 mRNA. J. Pharm. Biomed. Anal. 49(2), 534-539 (2009).
13. Bertolotto A, Sala A, Caldano M et al. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. J. Immunol. Methods 321(1-2), 19-31 (2007). (Pubitemid 46441209)
14. Yu Y, Piddington C, Fitzpatrick D et al. A novel method for detecting neutralizing antibodies against therapeutic proteins by measuring gene expression. J. Immunol. Methods 316(1-2), 8-17 (2006). (Pubitemid 44573211)
15. Lallemand C, Meritet JF, Erickson R et al. Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene. J. Interferon Cytokine Res. 28(6), 393-404 (2008). (Pubitemid 351929939)
16. Wei X, Swanson SJ, Gupta S. Development and validation of a cell-based bioassay for the detection of neutralizing antibodies against recombinant human erythropoietin in clinical studies. J. Immunol. Methods 293(1-2), 115-126 (2004). (Pubitemid 39468337)
17. Burman JP, Plackett RL. The design of optimum multifactorial experiments. Biometrika 33(4), 305-325 (1946).
18. Prakasham RS, Rao ChS, Rao RS, Lakshmi GS, Sarma PN. l-asparaginase production by isolated Staphylococcus sp. - 6A: design of experiment considering interaction effect for process parameter optimization. J. Appl. Microbiol. 102(5), 1382-1391 (2007). (Pubitemid 46646628)
19. Chen XC, Zhou L, Gupta S, Civoli F. Implementation of design of experiments (DOE) in the development and validation of a cell-based bioassay for the detection of anti-drug neutralizing antibodies in human serum. J. Immunol. Methods 376(1-2), 32-45 (2012).
20. Ray CA, Patel V, Shih J et al. Application of multi-factorial design of experiments to successfully optimize immunoassays for robust measurements of therapeutic proteins. J. Pharm. Biomed. Anal. 49(2), 311-318 (2009).
21. Joelsson D, Moravec P, Troutman M, Pigeon J, Dephillips P. Optimizing ELISAs for precision and robustness using laboratory automation and statistical design of experiments. J. Immunol. Methods 337(1), 35-41 (2008).
22. Mikulskis A, Yeung D, Subramanyam M, Amaravadi L. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development. J. Immunol. Methods 365(1-2), 38-49 (2011).
23. Sanchez S, Barger T, Zhou L et al. Strategy to confirm the presence of anti-erythropoietin neutralizing antibodies in human serum. J. Pharm. Biomed. Anal. 55(5), 1265-1274 (2011).
24. Lansky D. Strip-plot designs, mixed models, and comparisons between linear and non-linear models for microtitre plate bioassays. Dev. Biol. (Basel) 107, 11-23 (2002).
25. Finco D, Baltrukonis D, Clements-Egan A et al. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics. J. Pharm. Biomed. Anal. 54(2), 351-358 (2011).
26. US Department of Health and Human Services, US FDA. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Silver Spring, MD, USA (2012).
27. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348(7), 601-608 (2003). (Pubitemid 36204954)
28. Mccutcheon KM, Quarmby V, Song A. Development and optimization of a cell-based neutralizing antibody assay using a sample pre-treatment step to eliminate serum interference. J. Immunol. Methods 358(1-2), 35-45 (2010).
29. Lofgren JA, Wala I, Koren E, Swanson SJ, Jing S. Detection of neutralizing anti-therapeutic protein antibodies in serum or plasma samples containing high levels of the therapeutic protein. J. Immunol. Methods 308(1-2), 101-108 (2006). (Pubitemid 43107958)
30. Spengler M, Adler M, Jonas A, Niemeyer CM. Immuno-PCR assays for immunogenicity testing. Biochem. Biophys. Res. Commun. 387(2), 278-282 (2009).
31. Hu J, Gupta S, Swanson SJ, Zhuang Y. A bioactive drug quantitation based approach for the detection of anti-drug neutralizing antibodies in human serum. J. Immunol. Methods 345(1-2), 70-79 (2009).